SECsense Logo

LAVA Therapeutics NV 8-K Report: Key Financial Insights as of February 20, 2025

$LVTX
Form 8-K
Filed on: 2025-02-25
Source
LAVA Therapeutics NV 8-K Report: Key Financial Insights as of February 20, 2025

Based on the provided XML snippet from the financial report, here are the key pieces of information extracted:

  1. Entity Identification:
  • Company Name: LAVA Therapeutics NV
  • CIK: 0001840748
  • SEC File Number: 001-40241
  • Address: Yalelaan 62, Utrecht, NL 3584
  • Phone Number: +31 85 016 3100
  1. Filing Information:
  • Filing Type: 8-K
  • Filing Date: February 20, 2025
  1. Common Shares Information:
  • Nominal Value: €0.12 per share
  • Ticker Symbol: LVTX
  • Exchange: NASDAQ
  1. Reporting Context:
  • Report As of Date: February 20, 2025
  • Currency: USD
  • Units reported: Shares and USD per share
  1. Additional Notes:
  • The document is structured in XBRL format, which is used for financial reporting and allows for easier data extraction and analysis.
  • The filing is part of an ongoing reporting requirement under SEC regulations, indicating that the company is actively maintaining compliance with disclosure requirements.

This information can be useful for investors, analysts, and stakeholders interested in the financial performance and compliance of LAVA Therapeutics NV as of the specified date.